Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

  • STATUS
    Recruiting
  • participants needed
    150
  • sponsor
    Medical University of Vienna
Send
Updated on 5 August 2020
See if I qualify
cancer
basal cell carcinoma of the skin
melanoma of the skin

Summary

EXALT-2 is a prospective, randomized, three arm study for treatment decision guided either by either comprehensive genomic profiling, next generation drug screening or physician's choice

Details
Condition Refractory Acute Myeloid Leukemia, Refractory Leukemia, Advanced Lymphoma, Refractory Lymphoma, Refractory T-Cell Lymphoma
Age 18years - 100years
Treatment Next generation functional drug screening, Comprehensive genomic profiling
Clinical Study IdentifierNCT04470947
SponsorMedical University of Vienna
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

patient is suffering from aggressive haematological disease AND has undergone at least two lines of previous therapies AND/OR has undergone at least one previous therapy and no standard treatment is available in the specific disease setting and disease specific guidelines recommend treatment in studies
duration of last response is less than 6 months defined as first day of last treatment to date of relapse, the response duration has to be available with dates (dd/mm/yyyy) for initiation of and relapse to previous treatment
best response to previous treatment has to be available
The patient is able to give written informed consent and wishes to undergo further therapy
further therapy is medically feasible
tumor cell-containing samples can be obtained

Exclusion Criteria

current participation in another experimental clinical trial
performance status does not allow participation (ECOG 1)
pregnancy, tested at screening
patient suffers from classical or nodular, lymphocyte predominant Hodgkins lymphoma
other malignoma, diagnosed <1a before inclusion (except localized squamous cell carcinoma of the skin, surgically curable melanoma of the skin, basal cell carcinoma of the skin)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
basal cell carcinoma of the skin
melanoma of the skin

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.